The global influenza diagnostics market size was valued at USD 1.74 billion in 2025 and is projected to grow from USD 1.83 billion in 2026 to USD 2.81 billion by 2034 at a CAGR of 5.46% during the forecast period 2026-2034. North America dominated the influenza diagnostics market with a market share of 39.5% in 2025.
Influenza diagnostics refers to the methods and technologies used to detect and identify influenza virus infections in patients. These diagnostic approaches include rapid antigen tests, molecular assays, polymerase chain reaction (PCR) tests, viral culture, and immunofluorescence techniques. They help healthcare professionals accurately diagnose influenza, differentiate it from other respiratory illnesses, and support timely treatment decisions. Influenza diagnostics are widely used in hospitals, clinics, laboratories, and public health settings to improve patient care, monitor outbreaks, and support disease surveillance.
Download a Free Sample To learn more about this report,
Multiplex Molecular Testing Strengthens Respiratory Disease Detection
The influenza diagnostics market is evolving as healthcare providers increasingly adopt multiplex molecular tests that can detect influenza A, influenza B, COVID-19, and RSV from a single patient sample. These advanced PCR-based assays deliver faster and more accurate results than traditional diagnostic methods, enabling clinicians to begin appropriate treatment earlier and improve infection control. The growing need for rapid diagnosis during seasonal respiratory outbreaks is supporting influenza diagnostics market growth across hospitals, laboratories, and urgent care centers.
Point-of-Care Testing Expands Access to Rapid Influenza Diagnosis
Healthcare systems are increasingly investing in portable and point-of-care influenza diagnostic platforms that deliver results within minutes. These systems reduce waiting times, support timely antiviral treatment, and help healthcare providers distinguish influenza from other respiratory illnesses during peak flu seasons. The wider availability of compact molecular analyzers and rapid antigen tests is contributing to the increasing influenza diagnostics market size while improving access to testing in clinics, emergency departments, and community healthcare settings.
Increasing Seasonal Influenza Burden and Growing Adoption of Rapid Molecular Testing
The market is experiencing steady growth due to the increasing incidence of seasonal influenza and the need for rapid, accurate diagnosis to support timely clinical treatment and infection control. Healthcare providers are increasingly adopting molecular and point-of-care diagnostic technologies that deliver faster results with higher sensitivity than conventional rapid antigen tests. Government agencies and public health organizations continue to strengthen influenza surveillance and diagnostic capacity, significantly driving influenza diagnostics market demand. The growing availability of multiplex respiratory tests capable of detecting influenza alongside other respiratory viruses is further supporting market expansion.
Regulatory Requirements and Product Quality Challenges
The market faces restraints due to stringent regulatory approval processes, extensive clinical validation requirements, and continuous quality monitoring for influenza diagnostic products. Manufacturers must maintain consistent product performance while complying with evolving regulatory standards. Product corrections, recalls, or quality-related issues can increase operational costs, delay product availability, and affect customer confidence, particularly for point-of-care diagnostic systems.
Expansion of Home-Based and Multiplex Diagnostic Testing
The market presents significant opportunities through the growing demand for home-based diagnostics, multiplex molecular assays, and decentralized healthcare. Healthcare providers and consumers increasingly prefer tests capable of simultaneously detecting influenza, COVID-19, RSV, and other respiratory pathogens from a single sample. These developments represent some of the leading influenza diagnostics market trends, creating opportunities for manufacturers to expand rapid testing solutions across hospitals, clinics, pharmacies, and home healthcare settings.
Adapting Diagnostics to Emerging Influenza Strains
The market continues to face challenges as influenza viruses evolve rapidly through antigenic drift and the emergence of novel strains, requiring continuous updates to diagnostic assays and surveillance systems. Manufacturers must ensure high analytical accuracy while responding quickly to changing epidemiological conditions and regulatory expectations. These developments are comprehensively analyzed in the latest influenza diagnostics market report, helping stakeholders understand evolving diagnostic technologies, public health priorities, and future testing requirements.
Request Customizationto receive a tailored report.
Molecular Diagnostic Test Segment Dominated the Influenza Diagnostics Market with 54.8% Share in 2025
The molecular diagnostic test segment dominated the global influenza diagnostics market with a 54.8% share in 2025, driven by its high sensitivity, accuracy, and ability to rapidly detect influenza viruses, even in the early stages of infection. Molecular diagnostic techniques enable healthcare professionals to distinguish between influenza strains with greater precision, supporting timely treatment decisions and effective infection control. Growing adoption of advanced laboratory technologies, increasing demand for rapid and reliable diagnosis, and continued investments in molecular testing infrastructure continue to strengthen the demand for this segment.
The traditional diagnostic test segment continues to maintain a significant presence in the influenza diagnostics market due to its affordability, ease of use, and widespread availability across hospitals, clinics, and diagnostic laboratories. Rapid Influenza Diagnostic Tests (RIDTs) remain widely used for point-of-care screening because they provide quick results. Cell culture methods continue to support virus isolation and surveillance activities, while direct fluorescent antibody (DFA) tests and serological assays remain valuable in specific clinical and research settings where confirmatory or retrospective diagnosis is required.
RT-PCR Segment Dominated the Molecular Diagnostic Test Market with 61.3% Share in 2025
Within molecular diagnostics, the RT-PCR segment dominated the market with a 61.3% share in 2025 due to its exceptional accuracy, high sensitivity, and ability to detect influenza viruses within a short timeframe. RT-PCR has become the reference standard for influenza diagnosis in many healthcare settings because it supports early detection, differentiates influenza virus subtypes, and improves clinical decision-making.
The isothermal nucleic acid amplification technology (INNAT) segment continues to witness strong growth by offering faster testing with simplified workflows and minimal laboratory infrastructure requirements. Other molecular tests also contribute to the market by providing specialized diagnostic capabilities for research laboratories and advanced clinical applications.
LAMP Segment is Emerging as the Fastest-Growing INNAT Technology
Within the INNAT segment, loop-mediated isothermal amplification (LAMP) is witnessing particularly strong adoption because it delivers rapid and highly accurate molecular testing without requiring sophisticated thermal cycling equipment. The TMA segment continues to support high-throughput molecular testing in clinical laboratories, while NASBA remains valuable for RNA amplification in infectious disease diagnostics. Other INNAT technologies continue to expand as diagnostic developers introduce innovative molecular platforms designed to improve testing speed, accessibility, and operational efficiency.
Influenza A Segment is Projected to Register the Fastest Growth in the Influenza Diagnostics Market at a CAGR of 7.3%
The influenza A segment is projected to register the fastest growth in the influenza diagnostics market at a CAGR of 7.3% during 2026–2034, driven by its widespread prevalence, higher transmission rates, and greater potential to cause seasonal epidemics and occasional pandemics. Healthcare providers continue to prioritize rapid detection of Influenza A infections to enable early antiviral treatment, improve patient outcomes, and strengthen public health surveillance. Increasing government monitoring programs and improvements in molecular diagnostic technologies continue to support the expansion of this segment.
The influenza B segment continues to account for a substantial share of the market due to its regular contribution to seasonal influenza outbreaks. Although generally less widespread than Influenza A, accurate diagnosis of Influenza B remains essential for effective patient management, surveillance programs, and vaccination strategies.
Hospital Segment Dominated the Influenza Diagnostics Market with 38.6% Share in 2025
The hospital segment dominated the global influenza diagnostics market with a 38.6% share in 2025, driven by the high volume of patients requiring laboratory-confirmed influenza diagnosis and comprehensive clinical care. Hospitals continue to invest in advanced diagnostic technologies to enable rapid detection, support timely treatment decisions, reduce hospital-acquired infections, and improve patient outcomes. The availability of sophisticated laboratory infrastructure and skilled healthcare professionals further reinforces the segment's leading position.
The point-of-care testing segment continues to witness rapid growth as healthcare providers increasingly adopt portable diagnostic solutions that deliver results within minutes, enabling faster clinical decision-making in emergency departments, outpatient clinics, and community healthcare settings. The diagnostic centers segment remains an important contributor by providing specialized influenza testing services with high diagnostic accuracy and laboratory efficiency. The other segment, including public health laboratories, academic institutions, and research organizations, continues to support influenza surveillance, epidemiological studies, and the development of next-generation diagnostic technologies.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global influenza diagnostics market, representing 39.5% of total revenue and reaching USD 0.69 billion in 2025. The region continues to lead due to its advanced healthcare infrastructure, widespread availability of rapid diagnostic technologies, and strong focus on infectious disease surveillance. Increasing seasonal influenza testing, growing awareness of early disease detection, and continuous investments in molecular diagnostic technologies continue to support market growth across the region.
The US market was valued at approximately USD 0.60 billion in 2025, making it the largest contributor in North America. High testing volumes, increasing adoption of rapid molecular diagnostic assays, expanding public health initiatives, and strong investments in clinical laboratory infrastructure continue to strengthen market growth.
Canada's market reached approximately USD 0.09 billion in 2025. Growing emphasis on disease surveillance, rising use of point-of-care diagnostic tests, and continuous improvements in healthcare infrastructure are contributing to steady market growth.
Asia Pacific accounted for 21.8% of the global influenza diagnostics market, valued at USD 0.38 billion in 2025, and is projected to register the fastest CAGR of 8.5% during the forecast period. Rising healthcare expenditure, increasing awareness of infectious disease management, expanding diagnostic laboratory networks, and improving access to advanced testing technologies continue to drive regional market growth. Government initiatives to strengthen public health systems are further supporting market expansion.
Japan's market generated approximately USD 0.07 billion in 2025. Strong seasonal influenza surveillance programs, widespread adoption of rapid diagnostic tests, and advanced healthcare infrastructure continue to support market growth.
China accounted for the largest share of the Asia Pacific market, reaching approximately USD 0.22 billion in 2025. Expanding healthcare infrastructure, increasing investment in molecular diagnostics, growing public health awareness, and rising demand for rapid influenza testing continue to drive market expansion.
Europe represented 27.4% of the global influenza diagnostics market, reaching USD 0.48 billion in 2025, and is projected to grow at a CAGR of 6.6% during the forecast period. The regional market is supported by strong public healthcare systems, increasing adoption of advanced diagnostic technologies, and ongoing influenza surveillance programs. Rising demand for early diagnosis and improved infection control measures continues to contribute to long-term market growth.
The UK market was valued at approximately USD 0.11 billion in 2025. Increasing influenza screening, expanding laboratory testing capacity, and growing adoption of rapid diagnostic technologies continue to support market growth.
Germany's market accounted for approximately USD 0.13 billion in 2025. The country's well-established healthcare infrastructure, strong diagnostic laboratory network, and increasing use of molecular testing technologies continue to strengthen market expansion.
Middle East & Africa accounted for 4.9% of the global influenza diagnostics market, totaling USD 0.09 billion in 2025. Rising healthcare investments, expanding diagnostic capabilities, and growing awareness of infectious disease detection are supporting market growth across the region. Increasing government efforts to improve disease surveillance and healthcare preparedness are expected to create additional opportunities during the forecast period.
The UAE market was valued at approximately USD 0.02 billion in 2025. Government investments in healthcare modernization, increasing use of rapid diagnostic technologies, and expanding infectious disease monitoring programs continue to support market development.
Africa's market reached approximately USD 0.07 billion in 2025. Improving healthcare infrastructure, expanding access to diagnostic testing, increasing public health initiatives, and growing investment in infectious disease surveillance are creating long-term growth opportunities across the region.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Jay Mehta is a Research Analyst with over 4 years of experience in the Medical Devices industry. His expertise spans market sizing, technology assessment, and competitive analysis. Jay’s research supports manufacturers, investors, and healthcare providers in understanding device innovations, regulatory landscapes, and emerging market opportunities worldwide.
We are featured on:
sales@straitsresearch.com